New Data from PURPOSE Trials Further Demonstrate that Lenacapavir (Yeztugo ® ) was Effective and Well Tolerated Across a Broad Range of Populations, Including Pregnant and Lactating Women, Adolescents and Young People Data Also Showed Twice-Yearly Injectable PrEP was Preferred vs. Daily Oral Medication Among PURPOSE Trial Participants Gilead’s Research Presentations and Community Events at IAS Reflect Commitment to... Read More